Maryam Sadat

Maryam Sadat has a diverse work experience in the pharmaceutical and biotechnology industry. Maryam is currently the Vice President of Quality at Vir Biotechnology, Inc. (since March 2022) and previously served as the Senior Director and Head of Development Quality (May 2021 - March 2022) at the same company.

Prior to Vir Biotechnology, Maryam held the position of Executive Director of Development Quality and Compliance at Esperion - The Lipid Management Company (October 2020 - May 2021).

Maryam has an extensive tenure at Amgen, where they worked as the Director of GCP Compliance (October 2015 - October 2020) and as a Compliance Senior Manager (March 2012 - October 2015).

Maryam also gained experience at other organizations such as Micromet (Associate Director of QA, January 2011 - March 2012), MacroGenics (Associate Director of Clinical QA, January 2009 - December 2010; Sr. CQA Specialist, December 2008 - January 2009), SciReg, Inc. (Product Development Specialist, June 2008 - December 2008), International Partnership for Microbicides (Clinical Project Director, June 2005 - May 2008), Otsuka Pharmaceutical Development & Commercialization, Inc. (QA Associate, 2001 - 2004), and BioReliance (Auditor, 1995 - 2000).

Throughout their career, Maryam has held various leadership positions and made significant contributions in quality management and compliance within the industry.

Maryam Sadat completed their Bachelor of Science (BS) degree from The Ohio State University between 1992 and 1995. Prior to that, they studied biology at the University of Maryland Baltimore County from 1990 to 1992. Maryam then pursued a Master of Science (MS) degree in Biotechnology at The Johns Hopkins University in 1996.